What Is PTSD? Symptoms, Causes, and Treatment

Understanding PTSD: Definition and DSM-5 Criteria

Post-traumatic stress disorder (PTSD) is a mental health condition that can develop when a person is exposed to a traumatic event—or series of events—that involves actual or threatened death, serious injury, or sexual violence. The DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) defines four symptom clusters that must be present for at least one month and cause clinically significant distress or functional impairment.

The four clusters are: (1) intrusion symptoms—unwanted, distressing memories of the trauma, flashbacks (dissociative episodes where the event feels as though it is happening again), nightmares, and intense psychological or physiological reactions to trauma-related cues; (2) avoidance—efforts to avoid distressing thoughts, feelings, places, people, or activities related to the trauma; (3) negative alterations in cognition and mood—persistent negative beliefs about oneself or the world, distorted blame, persistent negative emotions (fear, horror, anger, guilt, shame), diminished interest in activities, detachment from others, and inability to experience positive emotions; and (4) alterations in arousal and reactivity—hypervigilance, exaggerated startle response, difficulty concentrating, irritability and angry outbursts, reckless or self-destructive behavior, and sleep disturbances.

Types of Trauma and Who Is Affected

PTSD can develop following many types of traumatic events: combat exposure (historically the most studied context), sexual assault, childhood abuse, serious accidents, natural disasters, terrorist attacks, sudden bereavement, and witnessing violence. Prolonged, repeated trauma—such as childhood sexual abuse or domestic violence—is associated with a more complex presentation sometimes called Complex PTSD (CPTSD), which features pervasive difficulties in emotional regulation, self-perception, and relationships, in addition to core PTSD symptoms.

Lifetime prevalence of PTSD is estimated at 6.8% in the United States and varies considerably across cultures and populations. Women are approximately twice as likely as men to develop PTSD following trauma, partly because of higher rates of sexual assault exposure. Risk factors for developing PTSD include prior trauma history, lack of social support, pre-existing anxiety or depression, peritraumatic dissociation (feeling detached from oneself during the trauma), and injury severity. Importantly, most people exposed to trauma do not develop PTSD—resilience factors such as strong social networks and adaptive coping strategies play a protective role.

The Neurobiology of Trauma

PTSD produces measurable changes in brain structure and function. The amygdala—the brain's fear-processing center—becomes hyperactive, responding with exaggerated alarm to trauma-related cues and even neutral stimuli. The prefrontal cortex, which normally regulates the amygdala's fear response through top-down inhibition, shows reduced activity and volume in PTSD, impairing the ability to distinguish genuine threats from safe situations. The hippocampus, involved in memory consolidation and contextualizing fear memories in time and place, shows volume reduction in PTSD, contributing to fragmented, time-distorted traumatic memories.

The hypothalamic-pituitary-adrenal (HPA) axis—the stress hormone system—is dysregulated in PTSD. Unlike the elevated cortisol seen in depression, PTSD is associated with low baseline cortisol but enhanced negative feedback sensitivity, producing a state of chronic biological stress readiness. Elevated norepinephrine levels contribute to hyperarousal symptoms. These neurobiological changes are not merely consequences of PTSD but actively perpetuate it, creating a self-sustaining cycle of fear and avoidance.

Evidence-Based Psychological Treatments

Trauma-focused cognitive behavioral therapy (TF-CBT) is one of the most well-validated treatments for PTSD, particularly in children and adolescents. It integrates psychoeducation, cognitive restructuring of trauma-related maladaptive thoughts, and gradual exposure to trauma-related memories and cues. Cognitive Processing Therapy (CPT) is a specific 12-session CBT protocol developed originally for sexual assault survivors that focuses on identifying and challenging stuck points—distorted beliefs about safety, trust, power, esteem, and intimacy arising from the trauma—through written accounts and Socratic dialogue.

Prolonged Exposure (PE) therapy involves systematic, repeated confrontation of avoided trauma memories (imaginal exposure) and real-world avoided situations (in vivo exposure) until the fear response is extinguished. It is one of the most empirically supported PTSD treatments across multiple trauma populations. Eye Movement Desensitization and Reprocessing (EMDR) is an eight-phase treatment in which the patient briefly focuses on distressing trauma memories while simultaneously engaging in bilateral sensory stimulation, most commonly therapist-directed side-to-side eye movements. Though the precise mechanism of EMDR remains debated, multiple randomized controlled trials demonstrate efficacy comparable to trauma-focused CBT.

Pharmacological Treatments

Two medications have FDA approval specifically for PTSD: sertraline (Zoloft) and paroxetine (Paxil), both selective serotonin reuptake inhibitors (SSRIs). Venlafaxine (an SNRI) also has strong evidence and is widely used off-label. These medications reduce PTSD symptom severity across all four clusters and are particularly useful when trauma-focused psychotherapy is not immediately available or is not tolerated. They typically require 8–12 weeks to show full effect and should be continued for at least 12 months.

Prazosin, an alpha-1 adrenergic blocker, has evidence for reducing trauma-related nightmares by blocking norepinephrine's effects on the brain during sleep. MDMA-assisted psychotherapy is an emerging breakthrough treatment—Phase 3 trials have shown unprecedented efficacy rates in treatment-resistant PTSD—though regulatory approval remains pending as of 2026. The combination of pharmacotherapy and trauma-focused psychotherapy is generally superior to either treatment alone.